Last reviewed · How we verify

NCT05745116

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT

Status unknown Last updated 27 February 2023
What this trial tests

trial testing Notal Vision Home OCT in Diabetic Macular Edema in 150 participants. Status unknown.

Timeline
7 November 2022
Primary endpoint
31 July 2023
31 July 2023

Quick facts

Lead sponsorNotal Vision Inc.
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date7 November 2022
Primary completion31 July 2023
Estimated completion31 July 2023
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Notal Vision Inc.

Who can join

Eligibility, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

Other Notal Vision Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing